Form 4: 89bio Director Michael R. Hayden Acquires 56,400 Stock Options
SEC Form 4 Filing
Director Michael R. Hayden acquired 56,400 stock options in 89bio, Inc. on February 3, 2025, according to a Form 4 filing.
Summary
- Michael R. Hayden, a director of 89bio, Inc., acquired 56,400 stock options on February 3, 2025.
- The options have an exercise price of $9.60.
- The options vest in full on February 1, 2026, contingent upon continued service to the issuer.
- The options expire on February 3, 2035.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition by a director. While insider buying can be seen as positive, option grants are part of compensation and don't necessarily indicate strong bullish sentiment.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. These filings provide transparency to the market.
Stakeholder Impact
- The acquisition of stock options by a director could potentially increase shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 02/03/2025 | Date of transaction: Michael R. Hayden acquired 56,400 stock options. |
| 02/01/2026 | Vesting date for the stock options, contingent upon continued service. |
| 02/03/2035 | Expiration date of the stock options. |
| 02/05/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.